Affiliations 

  • 1 Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University, Malaysia. Electronic address: CheongSiewLee@imu.edu.my
  • 2 Dipartimento di Scienze Chimiche e Farmaceutiche, Università degli Studi di Trieste, Italy
  • 3 Institut für Pharmakologie und Toxikologie, Universität Würzburg, Germany
  • 4 Department of Pharmacy, National University of Singapore, Singapore
Drug Discov Today, 2019 09;24(9):1769-1783.
PMID: 31102728 DOI: 10.1016/j.drudis.2019.05.003

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder characterized by degeneration of dopaminergic neurons. Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. Current treatment options provide symptomatic relief to the condition but are unable to reverse disease progression. The conventional single-target therapeutic approach might not always induce the desired effect owing to the multifactorial nature of PD. Hence, multitarget strategies have been proposed to simultaneously target multiple proteins involved in the development of PD. Herein, we provide an overview of the pathogenesis of PD and the current pharmacotherapies. Furthermore, rationales and examples of multitarget approaches that have been tested in preclinical trials for the treatment of PD are also discussed.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.